Per the PR about the MERCK and OPEXA option agreement, it seems to me that MERCK is interested potentially in Tcelna's effect on MS in general and not just on Tcelna's effect on SPMS. There really could be more news to come. Maybe that institution that bought shares read between the lines the way i am doing right now.
"Under the terms of the agreement, Opexa will receive an upfront payment of $5 million for granting an option to Merck Serono for the exclusive license of the Tcelna (imilecleucel-T) program for the treatment of MS. The option may be exercised prior to or upon completion of Opexa’s ongoing Phase IIb clinical trial in patients with SPMS. Upon exercising this licensing option, Merck Serono would pay an upfront license fee of either $25 million or $15 million (depending upon whether certain conditions are met), and in return receive worldwide development and commercial rights to Tcelna (imilecleucel-T) in MS, excluding Japan."
There is NO benefit for Merck to buy now? Give me one reason they would risk spending another $15-$25M now when nothing has changed? One! Here is the deal. There is no incentive for Merck to option now. THEY OWN THE RIGHTS NOW?
My guess is that you haven't bothered to read the 8-K regarding DETAILS of the agreement. RIGHT?
RRMS is mentioned a few times.They are optioning the rights of Tcelna for ANY TYPE of Auto Immune Disease! Get that? TCelna for ANY Auto Immune Disease. Lots of other uses of Tcelna than just MS.
Phase III has been given clearance from the FDA to start.
There are tremendous benefits, both Financially and Logistically, to start Phase III now.
This is the next upside in the stock. Announcement of Phase III run concurrently with Phase IIb. Another upside is the announcement of Who the agreement for Japan rights is with and for HOW MUCH!
Perhaps financial incentive. 15 versus 25 million dollar cost depending upon factual sceanrio on exercise day. Just spitballing. Have a good day and no need to stress out. Are you short or long the stock?